Bear of the Day: Elevance Health (ELV)

Elevance Health (ELV) reported weak quarterly results, with shares plunging after missing EPS estimates by over 3% and adjusted EPS falling 13% year-over-year, despite sales growing 14% to $49.4 billion. The company significantly cut its 2025 adjusted EPS guidance to $30.00 from a previously reaffirmed range of $34.15-$34.85, attributing the reduction to elevated cost trends in ACA and Medicaid. This substantial guidance revision has prompted analysts to adopt a bearish outlook, assigning ELV a Zacks Rank #5 (Strong Sell) and indicating a challenging near-term trajectory for the stock.

Analysis

Elevance Health (ELV) is facing significant headwinds, primarily driven by deteriorating profitability and a sharply revised forward outlook. The company's 2025 adjusted EPS guidance was drastically cut to $30.00, a substantial reduction from the $34.15-$34.85 range it had reaffirmed as recently as early May. This abrupt reversal signals a rapid and severe impact from what the company identifies as elevated cost trends within its ACA and Medicaid businesses, raising questions about management's near-term visibility. The guidance cut follows a weak quarterly report where adjusted EPS fell 13% year-over-year and missed consensus estimates by over 3%, causing the stock to plunge. While the company demonstrated top-line strength with sales growing 14% to $49.4 billion, this revenue growth is being completely offset by margin compression. The combination of a current earnings miss and a severe future guidance reduction has led analysts to adopt a strongly bearish stance, reflected in the stock's Zacks Rank #5 (Strong Sell) rating.

Key Decisions for Investors

• Given the severe guidance reduction and resulting Zacks Rank #5 (Strong Sell), investors should exercise extreme caution, and those with existing positions may consider trimming their exposure until there is evidence of cost stabilization.
• The key metric to monitor is the company's ability to manage medical cost trends; investors should scrutinize future reports for any improvement in profit margins or specific strategies to mitigate pressures from the ACA and Medicaid segments.
• The abruptness of the guidance revision raises concerns about management's credibility and forecasting ability, warranting a skeptical approach to future management commentary until a consistent track record of meeting targets is re-established.